MedTrace Logo

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

NCT00505830 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2007-07-25

No results posted yet for this study

Summary

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.

The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.

Secondary objectives are to:

Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.

Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.

Define the threshold of positivity for the 3 questionnaires.

Conditions

Interventions

OTHER

questionnaires

Primary outcome: Autism Spectrum Quotient (AQ) Secondary outcome measure: Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Sponsors & Collaborators

  • Joint Clinical Research Center

    collaborator OTHER

  • Groupe Francais d'Epidemiologie Psychiatrique

    lead OTHER

Principal Investigators

  • Sabine Manificat, MDH · Centre Hospitalier Saint Jean de Dieu

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Completion
2009-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505830 on ClinicalTrials.gov